REGULATED PRESS RELEASE published on 03/14/2024 at 07:01, 2 years 4 months ago bioMérieux – 2023 Financial Results
BRIEF published on 03/04/2024 at 11:42, 2 years 5 months ago BioMérieux annonce ses chiffres de droits de vote pour février 2024 Droits De Vote Capital Social BioMérieux Réglementation Février 2024
BRIEF published on 03/04/2024 at 11:42, 2 years 5 months ago BioMérieux announces its voting rights figures for February 2024 Share Capital Voting Rights BioMérieux Regulation February 2024
REGULATED PRESS RELEASE published on 03/04/2024 at 11:37, 2 years 5 months ago Février 2024 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant bioMérieux communique les informations mensuelles sur le nombre total de droits de vote et d'actions. Date d'arrêt : 29/02/2024 Communication Financière Droits De Vote BioMérieux Actions Informations Mensuelles
REGULATED PRESS RELEASE published on 02/02/2024 at 17:49, 2 years 6 months ago Janvier 2024 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant bioMérieux : Informations mensuelles sur le nombre total de droits de vote et d’actions au 31/01/2024 Autorité Des Marchés Financiers Droits De Vote BioMérieux Actions Informations Mensuelles
ARTICLE published on 01/16/2024 at 07:56, 2 years 6 months ago bioMérieux renforce son équipe de direction avec l'arrivée de deux nouveaux membres bioMérieux, amorce une phase de renouvellement stratégique avec l'incorporation de nouveaux directeurs pour ses divisions Affaires Médicales et R&D Innovation BioMérieux Diagnostic In Vitro Affaires Médicales Recherche Et Développement
REGULATED PRESS RELEASE published on 01/16/2024 at 07:01, 2 years 6 months ago bioMérieux nomme deux nouveaux membres dans son Comité de Direction pour diriger les Affaires Médicales et la R&D bioMérieux nomme deux nouveaux membres dans son Comité de Direction pour diriger les Affaires Médicales et la R&D BioMérieux Affaires Médicales Nominations Comité De Direction R&D
REGULATED PRESS RELEASE published on 01/16/2024 at 07:01, 2 years 6 months ago bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D bioMérieux, a world leader in in vitro diagnostics, announces the appointment of two new Executive Committee members, Dr. Charles K. Cooper and Céline Roger-Dalbert, to lead Medical Affairs and Research & Development, respectively. Dr. Cooper brings extensive medical and leadership background from Siemens Healthcare Diagnostics and U.S. Food & Drug Administration, while Céline Roger-Dalbert boasts over 25 years of in vitro diagnostic experience, with significant contributions to new product launches and over 20 patent applications. Their nominations signify bioMérieux's commitment to addressing global patients' needs and driving innovation, aligning with the company's strategy. For more information, visit www.biomerieux.com. BioMérieux Medical Affairs Research And Development In Vitro Diagnostics Executive Committee Members
ARTICLE published on 01/08/2024 at 09:15, 2 years 7 months ago bioMérieux enrichit son arsenal contre l'antibiorésistance en acquérant LUMED L'entreprise bioMérieux consolide sa présence dans le milieu de la santé en rachetant LUMED, expert en logiciels d'aide à la décision clinique BioMérieux LUMED Diagnostic In Vitro Antibiorésistance Logiciels De Santé
REGULATED PRESS RELEASE published on 01/08/2024 at 08:22, 2 years 7 months ago bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance bioMérieux has acquired LUMED, a software company specializing in clinical decision support systems to optimize antimicrobial prescriptions and monitor healthcare-associated infections. This acquisition reinforces bioMérieux's commitment to combat antimicrobial resistance and improve infection prevention and control through advanced software solutions. BioMérieux LUMED Antimicrobial Resistance Clinical Decision Support System Infection Prevention And Control
Published on 08/07/2026 at 23:15, 1 day 1 hour ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 1 day 1 hour ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 1 day 2 hours ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 1 day 2 hours ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/08/2026 at 16:25, 8 hours 9 minutes ago Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 1 day 1 hour ago EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 1 day 5 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 1 day 5 hours ago ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:54, 1 day 5 hours ago Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 1 day 5 hours ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 1 day 5 hours ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 1 day 5 hours ago Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 1 day 6 hours ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026